Today’s article notes that it takes almost $1 billion to bring a new drug to market, stifling competition and allowing drug companies to charge Americans exorbitant amounts for the drugs they require. However, new legislation recently signed into law – the 21st Century Cures Act – seeks to streamline the approval process and bring new drugs to market faster, which the author notes “could be a boon for Big Pharma.” So, how can investors profit from this boon? The author highlights two top players in the generic pharmaceutical sector – as well as a biotech ETF that “gives you exposure to potentially huge moves from the little guys” – to consider. To read more, CLICK HERE.
The 21st Century Cures Act: How Investors Can Profit From This Potential “Boon For Big Pharma”
Tags:Big PharmaBiotechDrug CompaniesDrug CompanyETFInvestInvestmentInvestorPharma StocksPharmaceutical SectorProfitstock marketstocks